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A B S T R A C T
Introduction: The purpose was to investigate the usefulness of ADCratio on Diffusion MRI to discriminate between
benign and malignant lesions of Prostate.
Methods: Images of patients who underwent in-gantry MRI guided prostate lesion biopsy were retrospectively
analyzed. Prostate Cancers with 20% or more Gleason score (GS) pattern 3+ 3=6 in each core or any volume
of higher Gleason score pattern were included. ADCratio was calculated by two reviewers for each lesion. The
ADCratio was calculated for each lesion by dividing the lowest ADC value in a lesion and highest ADC value in
normal prostate in peripheral zone (PZ). ADCratio values were compared with the biopsy result. Data was ana-
lysed using independent samples T-test, Spearman correlation, intra-class correlation coefficient (ICC) and
Receiver operating characteristic (ROC) curve.
Results: 45 lesions in 33 patients were analyzed. 12 lesions were in transitional zone (TZ) and 33 in perpheral
zone PZ. All lesions demonstrated an ADCratio of 0.45 or lower. GS demonstrated a negative correlation with both
the ADC value and ADCratio. However, ADCratio (p < 0.001) demonstrated a stronger correlation compared to
ADC value alone (p= 0.014). There was no significant statistical difference between GS 3+4 and GS 4+3
mean ADCtumour value (p= 0.167). However when using ADCratio, there was a significant difference (p=0.032).
ROC curve analysis demonstrated an area under the curve of 0.83 using ADCratio and 0.76 when using ADCtumour
value when discriminating Gleason 6 from Gleason ≥7 tumours. Inter-observer reliability in the calculation of
ADC ratios was excellent, with ICC of 0.964.
Conclusion: ADCratio is a reliable and reproducible tool in quantification of diffusion restriction for clinically
significant prostate cancer foci.
1. Introduction
Diffusion weighted imaging (DWI) is one of the important compo-
nents of the multi-parametric MRI (mpMRI) examination of the pros-
tate. DWI can be quantitatively measured by Apparent Diffusion
Coefficient (ADC). There is wide evidence in current literature that
clinically significant prostate cancer foci demonstrate a reduction in
apparent diffusion coefficient (ADCtumour) and show restricted diffusion
relative to normal prostate tissue [1,2]. ADCtumour values obtained from
these maps correlate inversely with the histologic Gleason score for the
tumour [3–5] and are also associated with clinical outcomes [6,7].
According to the latest Prostate Imaging Reporting and Data System
(PIRADS) version 2 guidelines, interpretation and scoring of DWI and
ADC maps on mpMRI examination is based primarily on qualitative
visual assessment of the signal intensity of a lesion compared with that
of the surrounding normal prostatic tissue in the same anatomic zone,
to determine a significant reduction in ADC value within a suspected
lesion [2,8].
The guidelines acknowledge substantial overlap of ADC values
among different pathologies in prostate like stromal hyperplasia, low-
grade cancer, and high-grade cancer. Also, there is substantial varia-
bility in ADC values depending on multiple technical factors such as
vendor, field strength, and DWI acquisition parameters [2,8]. The ADC
values of Prostate Cancer (PCa) also vary according to age and race of
the patient [9]. There is no agreed ADCtumour value cut-off that could be
reliably used to determine abnormally low ADC within a lesion [4,5].
Nonetheless, in PI-RADS version 2, a threshold of 750–900mm2/s is
suggested as lesions with an ADC value that is less than this range tend
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to represent clinically significant prostate cancer. However, given the
noted variability, it has been recommended that each center should
identify its own thresholds that are based on internal data and com-
parisons with histopathologic findings. [2,8]. This independent ver-
ification of appropriate threshold can be difficult to establish. Also,
comparison between studies from two different centres would be dif-
ficult. Previous studies have shown wide variation in ADCtumour values
of both PCa as well as normal prostate [10].
A ratio of ADC values (ADCratio) between a lesion and the back-
ground prostate can potentially negate these external factors and pro-
vide a more accurate representation of change in the diffusion in a
tumour with respect to normal tissue. We calculated ADCratio for each
lesion by dividing the lowest ADC value in a lesion and highest ADC
value in PZ of normal prostate.
The aim of this study is to investigate the usefulness of ADCratio
values of a prostatic lesion to background prostate parenchyma to
discriminate between benign and malignant lesions. Also, we aim to
establish whether ADCratio is easily reproducible.
2. Material and methods
2.1. Patients
Our institutional review board (Human research and ethics com-
mittee) approved this retrospective study. We searched our database for
lesions that underwent in-gantry MRI guided biopsy between February
2013 and December 2014. 229 lesions that were biopsied via in-gantry
MR guided biopsy were retrospectively evaluated. Significant lesions
were considered to be lesions which demonstrated 20% or more
Gleason score (GS) pattern 3+3=6 in each core or any volume of
higher Gleason score pattern. Finally, 45 lesions in 33 patients were
included in the analysis. 33 tumours were in peripheral zone, and 12
were in transitional zone. Patient cohort characteristics are demon-
strated in Table 2. All the MRI studies were performed before any
prostate biopsy (biopsy-naïve lesions). Median PSA in this cohort was
7.8 ng/mL (range 1.8–26.0) and mean age was 67 years (range 49–81
years).
Fig. 1. A. Peripheral Zone lesion with Gleason score 4+ 5 tumor. Axial ADC image with ADC ratio of 0.26. B. Corresponding Axial T2 image of a TZ/PZ lesion.
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2.2. Diffusion weighted (DWI) MRI technique
All MRI examinations were performed on our 3.0-T system (Ingenia,
Philips Healthcare, Netherlands). Axial single-shot echo-planar diffu-
sion-weighted imaging (DWI) (FOV: 16 cm, TR range: (4000–5000), TE:
75 ms, Flip angle: 90°, 6 signal averages, Sense (parallel imaging factor)
2, 3 mm slice thickness with no inter-slice gap, voxel size of
1.8× 1.8 mm, B factor: 0, 100, 600, 1800s/mm2) was performed with
reconstruction of the apparent diffusion coefficient (ADC) map using a
standard mono-exponential. B0 was excluded from ADC calculations to
avoid perfusion artifacts. T2-weighted images in 3 planes, Axial T1-
weighted and dynamic contrast enhanced images were also obtained in
all the patients to complement diffusion-weighted images. The total
examination time was approximately 40min.
2.3. In-gantry MRI guided biopsy technique
A team comprising of an experienced Radiologist (RJ) and single
Urologist (HZH) performed in-gantry MRI guided core biopsies on all
the patients included in this study using Invivo DynaTRIM device
(Invivo Inc., Gainesvile, FL, USA). Prebiopsy MRI scan was performed
and the co-ordinates of the target lesion were analyzed with DynaCAD’s
interventional planning software to enable accurate targeting. MRI
compatible needle was introduced by transrectal route through a needle
sleeve which works as a guide as well as fiducial marker. Biopsy sam-
ples were obtained by using an MR-compatible, 18-gauge fully auto-
matic core-needle double-shot biopsy gun (Invivo) with a needle length
of 175mm and a tissue core sampling length of 17mm. Five core biopsy
samples were obtained from each lesion.
2.4. DWI analysis
All the lesions were marked for two readers (RJ, LH) who retro-
spectively analysed them on DWI scans. The lowest ADC value within
each lesion was calculated by drawing multiple circular region of in-
terest (RoI) of 5–10mm2 in each lesion and then the lowest value was
selected as ADCtumour. Similarly, multiple RoI were drawn within
normal peripheral zone (PZ) tissue displaying normal signal char-
acteristics on T1 and T2WI to calculate highest ADC value. Areas of low
T2 signal were excluded while calculating ADC of normal prostate to
avoid any area of scarring and inflammation. Areas of high T1 signal
were excluded to avoid haemorrhage. The ADCratio was calculated for
each lesion by dividing the lowest ADC value in a lesion and highest
ADC value in normal prostate in PZ.
Radiologist (RJ-first reader with experience of reading over 2000
prostate MRI examinations at 3.0 T) as well as a urology registrar (LH-
second reader, with no significant experience in reading mpMRI ex-
amination of prostate) independently calculated ADCratio for each lesion
(Fig. 1). Both the readers were blinded to the actual biopsy result. The
ADCratio was then analyzed with respect to the histological findings
from the biopsy.
2.5. Statistical analysis
Intraclass correlation coefficient analysis was conducted to
determine the reliability of calculating the ADCratio. Mean ADCtumour
and ADCratio scores were compared using independent samples T-test.
Spearman correlation was used to measure the strength of relationship
between ADC measurements (both ADCtumour and ADCratio) and the
observed Gleason score. Receiver operating characteristic (ROC) curve
analysis was calculated to assess the ability to discriminate between
different Gleason scores based on ADCtumour value and ADCratio. A P
value of< 0.05 was considered statistically significant for all statistical
analyses performed. Statistical analysis was performed using software
SPSS 24 (IBM).
3. Results
45 tumours were included in the present study. 33 tumours were in
peripheral zone, and 12 were in transitional zone. All Gleason
3+3=6 lesions and higher demonstrated an ADCratio of 0.45 or
lower. Of the 12 transitional zone lesions, the highest ADCratio value
was 0.43. Of the 33 peripheral zone lesions, the highest ADCratio was
0.45.
Inter-rater reliability in the calculation of ADC ratios was excellent,
with an intra-class correlation coefficient of 0.964.
There was no significant statistical difference between Gleason
3+4 and Gleason 4+3 mean ADCtumour value (p= 0.167), however
when using ADCratio there was a significant difference (p=0.032).
The association between the ADC measurements and the observed
Gleason score demonstrated a negative correlation when using both the
ADCtumour value (−0.365) as well as the ADCratio (−0.511). These re-
lationships were both significant (p=0.014 and p= < 0.001) re-
spectively. The ADC ratio demonstrated a stronger correlation when
compared with the ADCtumour value alone. This trend was observed
when stratified by zonal origin, and is presented in Table 1.
ROC curve analysis (Fig. 2) demonstrated an area under the curve of
0.83 using ADCratio and 0.76 when using ADCtumour value when dis-
criminating Gleason 6 from Gleason ≥7 tumours. The area under the
curve decreased for both ADCtumour value and ADCratio when dis-
criminating between Gleason 3+ 4 and Gleason 4+ 3 tumours (0.66
and 0.72 respectively).
4. Discussion
We found that tumour foci in both TZ and PZ show reduction of
ADC values compared to the normal prostate. There is progressive re-
duction of both ADCtumour as well as ADCratio values with increase in the
GS (Fig. 3). The ADCratio demonstrated a stronger correlation when
compared with the ADCtumour value alone. This correlates well with
results of previous studies [11–14].
While the present study is underpowered due to a low N, we have
demonstrated that the ADCratio is not inferior to the ADCtumour. in dis-
criminating GS 7 (3+ 4) and GS 7 (4+3) tumours. The trend observed
is that the ADCratio may in fact be superior to the ADCtumour, and as such
further investigation is required. The trend observed in this study was
consistent with findings from Boesen et al. [14].
It has been established that patients with GS 7(4+3) tumours have
Table 1
Spearman rho Correlation between ADC Measurements and Gleason Score
Overall for All Tumours and Stratified by Zonal Origin.
Spearman Rho
Zone ADC tumour ADC ratio
Peripheral −0.441 (p= 0.01) −0.561 (p=0.001)
Transitional −0.211 (p= 0.50) −0.402 (p=0.19)
Overall −0.365 (p= 0.014) −0.511 (p≤ 0.001)
Table 2
Patient characteristics.
Mean age of patients 67 years (range 49–81 years)
PSA level 7.8 ng/mL (range 1.8–26.0)
Lesion size median 11mm (range 7–23mm)
Location of lesions 33 in PZ, 12 in TZ
Gleason score (GS) of lesions GS 6=18
GS 7 (3+ 4)= 16
GS 7 (4+ 3)= 5
GS 8=5
GS 9=1
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a worse prognosis [15,16].
ROC curve analysis demonstrated an area under the curve (AUC) of
0.83 using ADCratio and 0.76 when using ADCtumour value when dis-
criminating Gleason 6 from Gleason ≥7 tumours. This compares with
AUC of 0.8 using ADCratio and 0.73 when using ADCtumour value as per
the study of Boesen et al. [14].
We chose a small RoI size of 5–10mm2 to try and find an area of the
lowest ADC value in a lesion, as lower ADC values have shown to
correspond to higher Gleason grade [3–5]. Larger RoI including ma-
jority of a lesion may potentially cause averaging of the ADC values.
Other investigators have used different size of RoI. Barrett et al. used
ROI of mean size 30mm2 in the PZ and 33mm2 in the TZ, although
there was a wide size range [12]. Boesen, Lebovici and Cobelli et al.
used a RoI encompassing the tumour centre while avoiding tumour
edges [11,13,14]. Interestingly, all these studies also found ADCratio to
be more useful than ADCtumour values in diagnosis of PCa. There has
Fig. 2. ROC-curve analysis for determining tumor aggressiveness (GS) using ADC tumor value and ADCratio for all tumors to discriminate between (A) GS 6 and
GS≥ 7 and between (B) GS≤ 7(3+4) and GS≥ 7(4+ 3).
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been no study in literature demonstrating the appropriate size of a RoI
that should be obtained for ADC measurements.
The biggest challenge for this study was to determine reproduci-
bility of ADCratio while considering a range of reader experience. Inter-
reader reliability in the calculation of ADC ratios was excellent, with an
intra-class correlation coefficient of 0.964. Due to its simplicity,
ADCratio has potential to become a universal tool in determining re-
duction in ADC while evaluating mpMRI studies. Lesion to normal
prostate ADCratio is easily calculated and can be used in daily practice
without having the need to use new software or formulae.
The previous studies in literature evaluating ADCratio have used
different methods to obtain pathology samples. Lebovici et al. [11] used
results of transrectal ultrasound guided biopsy with 20 cores to retro-
spectively identify a sector with positive Gleason result, rather than
targeting a particular lesion identified on mpMRI on biopsy naïve pa-
tients with MRI in gantry biopsy, as in our study. Ultrasound guided
core biopsy [13] and histopathological examination of prostatectomy
specimen [12–14] have also been used. Regardless of the method of
acquiring pathology specimen, ADCratio has been proven to be useful in
all these studies.
Fig. 3. Correlation of ADCtumour and ADCratio values with Gleason score.
A and B, Box-and-whisker plots show correlation of ADCtumour values (A) and tumor ADCratio (B) with Gleason score. Top and bottom of boxes represent 25th and
75th percentiles of data, with line in box representing median value.
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Use of ADCratio as a parameter may improve tumour characteriza-
tion, may provide a greater standardization and may allow a more ro-
bust comparison between different centers and across MRI platforms
[12–14].
One of the strengths of our study is performance of ingantry MRI
guided biopsy (MRGB) on all lesions, enabling accurate targeting of the
prostate lesions. MRGB has been shown to be superior to Transrectal
Ultrasound guided biopsies [17]. Also, all the MRI examinations were
performed using state of the art 3T MRI with DWI scans including high
B value of 1800s/mm2. Acquisition of “High b-value” images utilising a
b-value of more than 1400s/mm2 has been recommended in the latest
PIRADS v2 guidelines [8].
Our study has several limitations. The first is limitation inherent to
retrospective analysis. The final pathology on radical prostatectomy
would be a more accurate gold standard. Also, the sample size is small.
A study with larger number of patients would be needed to further
evaluate the usefulness of ADCratio and determine universally accep-
table cut-offs. Besides, our study is based on analysis of mpMRI images,
which is unable to distinguish all significant PCa lesions [18]. Detection
rates can be influenced by tumour Gleason score, histological volume,
histological architecture and location [19].
5. Conclusion
ADCratio has a potential to be a reliable and reproducible tool in
quantification of diffusion restriction for clinically significant PCa foci.
Due to its simplicity, it could replace the current practice of visual
analysis of ADCtumour reduction, and provide a more accurate objective
tool. Our results add to the growing evidence of usefulness of ADCratio
for MRI diagnosis of PCa.
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